Differential effect of tetradecythioacetic acid on the renin-angiotensin system and blood pressure in SHR and 2-kidney, 1-clip hypertension

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 3, 2007, Pages

  Bivol, Liliana Monica ^a,b   Berge, Rolf Kristian ^a,b   Iversen, Bjarne Magnus ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiotensin I; Angiotensin II

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; FATTY ACID DERIVATIVE; RENIN; TETRADECYTHIOACETIC ACID; THIOACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOWN REGULATION; HYPERTENSION; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; SYSTOLIC BLOOD PRESSURE;

EID: 34548640812     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00140.2007     Document Type: Article

References (34)

1. Aarsland A, Aarsaether N, Bremer J, Berge RK. Alkylthioacetic acids (3-thia fatty acids) as nonbeta-oxidizable fatty acid analogues: a new group of hypolipidemic drugs. III. Dissociation of cholesterol- and triglyceride-lowering effects and the induction of peroxisomal beta-oxidation. J Lipid Res 30: 1711-1718, 1989.
2. Amiri F, Garcia R. Renal angiotensin II receptor regulation in twokidney, one clip hypertensive rats: effect of ACE inhibition. Hypertension 30: 337-344, 1997.
3. Berge K, Tronstad KJ, Flindt EN, Rasmussen TH, Madsen L, Kristiansen K, Berge RK. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 22: 1747-1755, 2001.
4. Berge RK, Hvattum E. Impact of cytochrome P450 system on lipoprotein metabolism. Effect of abnormal fatty acids (3-thia fatty acids). Pharmacol Ther 61: 345-383, 1994.
5. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 13: 295-304, 2002.
6. Bivol LM, Vagnes OB, Iversen BM. The renal vascular response to ANG II injection is reduced in the nonclipped kidney of two-kidney, one-clip hypertension. Am J Physiol Renal Physiol 289: F393-F400, 2005.
7. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96: 354-360, 1995.
8. Cervenka L, Horacek V, Vaneckova I, Hubacek JA, Oliverio MI, Coffman TM, Navar LG. Essential role of AT1A receptor in the development of 2K1C hypertension. Hypertension 40: 735-741, 2002.
9. Cervenka L, Wang CT, Mitchell KD, Navar LG. Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 33: 102-107, 1999.
10. Cheng HF, Wang JL, Vinson GP, Harris RC. Young SHR express increased type 1 angiotensin II receptors in renal proximal tubule. Am J Physiol Renal Physiol 274: F10-F17, 1998.
11. Clozel JP, Muller RK, Roux S, Fischli W, Baumgartner HR. Influence of the status of the renin-angiotensin system on the effect of cilazapril on neointima formation after vascular injury in rats. Circulation 88: 1222-1227, 1993.
12. De Cavanagh EM, Piortkowski B, Fraga CG. The interaction between the renin-angiotensin system and peroxisome proliferator activated receptors: a hypothesis including the participation of mitochondria in aging. Front Biosci 12: 1049-1062, 2007.
13. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol Regul Integr Comp Physiol 265: R726-R732, 1993.
14. Fujishima S, Ohya Y, Nakamura Y, Onaka U, Abe I, Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens 11: 1134-1137, 1998.
15. Guan S, Fox J, Mitchell KD, Navar LG. Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats. Hypertension 20: 763-767, 1992.
16. Gudbrandsen OA, Hultstrom M, Leh S, Monica Bivol L, Vagnes O, Berge RK, Iversen BM. Prevention of hypertension and organ damage in 2-kidney, 1-clip rats by tetradecylthioacetic acid. Hypertension 48: 460-466, 2006.
17. Iversen BM, Sekse I, Ofstad J. Resetting of renal blood flow autoregulation in spontaneously hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 252: F480-F486, 1987.
18. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 17: 707-719, 1991.
19. Mrowka R, Steinhage K, Patzak A, Persson PB. An evolutionary approach for identifying potential transcription factor binding sites: the renin gene as an example. Am J Physiol Regul Integr Comp Physiol 284: R1147-R1150, 2003.
20. Navar LG. The role of the kidneys in hypertension. J Clin Hypertens (Greenwich) 7: 542-549, 2005.
21. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316-322, 2002.
22. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 13: 170-176, 1998.
23. Nishiyama A, Seth DM, Navar LG. Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension. J Hypertens 21: 1897-1903, 2003.
24. Okunishi H, Kawamoto T, Kurobe Y, Oka Y, Ishii K, Tanaka T, Miyazaki M. Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 18: 649-659, 1991.
25. Oparil S. The sympathetic nervous system in clinical and experimental hypertension. Kidney Int 30: 437-452, 1986.
26. Persson PB, Skalweit A, Mrowka R, Thiele BJ. Control of renin synthesis. Am J Physiol Regul Integr Comp Physiol 285: R491-R497, 2003.
27. Saynavalammi P, Porsti I. Angiotensin-converting enzyme inhibition with quinapril (CI-906) and captopril in spontaneously hypertensive rats with suppressed renin-angiotensin system. Methods Find Exp Clin Pharmacol 9: 325-331, 1987.
28. Shiono K, Sokabe H. Renin-angiotensin system in spontaneously hypertensive rats. Am J Physiol 231: 1295-1299, 1976.
29. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48: 1448-1453, 1999.
30. Wang X, Aukland K, Iversen BM. Autoregulation of total and zonal glomerular filtration rate in spontaneously hypertensive rats during antihypertensive therapy. J Cardiovasc Pharmacol 28: 833-841, 1996.
31. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD, Kratchmarova I, Berge RK, Iversen L, Bolund L, Kragballe K, Kristiansen K. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 116: 702-712, 2001.
32. Zhang R, Liao J, Morse S, Donelon S, Reisin E. Kidney disease and the metabolic syndrome. Am J Med Sci 330: 319-325, 2005.
33. Zhou X, Frohlich ED. Analogy of cardiac and renal complications in essential hypertension and aged SHR or L-NAME/SHR. Med Chem 3: 61-65, 2007.
34. Zou LX, Hymel A, Imig JD, Navar LG. Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. Hypertension 27: 658-662, 1996.